ITOS

iTeos Therapeutics (ITOS)

About iTeos Therapeutics (ITOS)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Details

Daily high

$7.90

Daily low

$7.65

Price at open

$7.69

52 Week High

$18.75

52 Week Low

$7.09

Market cap

283.5M

Dividend yield

0.00%

Volume

409,316

Avg. volume

505,053

P/E ratio

-2.46

iTeos Therapeutics News